You are here: Industry Insights > 2019

News List

A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019 PharmaSources/Caicai
December 24, 2020
Information on the top ten best-selling oncology drugs in China and the U.S. in 2019 has recently been released by a related consulting agency of the industry.
Sales of Zai Lab’s PARP Inhibitor Reaching RMB46.90 Million in Macau, S.A.R., China and Hong Kong, S.A.R., China of China in 2019 PharmaSources/Caicai
March 31, 2020
According to the 2019 results and company progress released by Zai Lab on Mar. 19, the total sales revenue of niraparib (trade name: Zejula) reached USD6.60 million (around RMB46.90 million) in Hong Kong, S.A.R., China and Macau, S.A.R., China Region of C
WuXi Biologics Achieved Remarkable Results in 2019 Wuxi Biologics
March 27, 2020
WuXi Biologics Achieved Remarkable Results in 2019, and is working to defeat COVID-19.
A Review of the Anticancer Drugs Approved in China in 2019 PharmaSources/Yefenghong
February 06, 2020
A review of the 7 blockbuster innovative oncology drugs approved by the NMPA (National Medical Products Administration of China) in 2019.
FDA antibody biosimilar product approvals increase in 2019 europeanpharmaceuticalreview
August 12, 2019
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
A Review of U.S. ANDA Approvals Received by Chinese Pharmaceutical Enterprises in the First Half of 2019 PharmaSources/Caicai
July 16, 2019
41 Approval Numbers, Multiple Blockbuster Varieties
Overview of the Approval Trends of Pharmaceutical Products in the First Half of 2019 PharmaSources/Suyi
July 11, 2019
Clinically Imperative Overseas New Drugs Approved Accounting for a Larger Number
Evolving World of Pharma: Three big trends to have impact on Pharma 2019 Sarah Harding
April 09, 2019
These are three big ones that I think could have a particularly interesting impact on Pharma this year: Innovation, Bio-manufacturing and Artificial Intelligence
ISCR welcomes new drugs and clinical trial rules, 2019 expressbpd
March 27, 2019
New rules well balanced, focused on patient rights, safety and well-being
Japan solid dose market predicted to bloom in 2019 cphi-online
March 07, 2019
Executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and the second fastest overall country for biologicals growth.

Previous page 1 2 3 Next page